Drug intelligence / Profile preview

GeloRevoice

Development stage: Unknown
Lead developer: Pohl-Boskamp
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Oral

Overview

GeloRevoice is a throat lozenge product developed and marketed by G. Pohl-Boskamp, specifically designed to alleviate symptoms of throat irritation, hoarseness, and dry mucous membranes. The product contains a unique 'Revoice Hydrogel Complex' consisting of xanthan gum, carbomer, and sodium hyaluronate. When dissolved in the mouth, these ingredients interact with saliva to form a long-lasting, protective hydrogel film that coats the oral and pharyngeal mucosa. This film acts as a physical barrier against external irritants and promotes the hydration of the throat, making it a preferred choice for professional voice users such as singers and speakers. It is classified as a medical device in many jurisdictions.

Brand names: GeloRevoice
Other names: GeloRevoice Throat Lozenges

Beyond the preview

Go deeper on GeloRevoice.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GeloRevoice.

Explore the full profile